Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

0.6955 -0.0192 (-2.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 729,852
Open 0.7300
Bid (Size) 0.7245 (1)
Ask (Size) 0.7450 (150)
Prev. Close 0.7147
Today's Range 0.6700 - 0.7345
52wk Range 0.6500 - 7.030
Shares Outstanding 62,819,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
10 Biggest Price Target Changes For Tuesday
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday. 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga

Performance

YTD
-81.70%
-81.70%
1 Month
-27.70%
-27.70%
3 Month
-50.32%
-50.32%
6 Month
-81.84%
-81.84%
1 Year
-86.55%
-86.55%

More News

Read More
Syros Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Earnings Scheduled For May 16, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Earnings Preview For Syros Pharmaceuticals
Via Benzinga
Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
From Syros Pharmaceuticals
Via Business Wire
66 Biggest Movers From Yesterday
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Via Benzinga
Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022
From Syros Pharmaceuticals
Via Business Wire
60 Biggest Movers From Yesterday
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
55 Biggest Movers From Friday
Via Benzinga
Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Recap: Syros Pharmaceuticals Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Via Benzinga
Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals's Earnings: A Preview
Via Benzinga
Syros to Participate in Upcoming Virtual Investor Conferences in March
From Syros Pharmaceuticals
Via Business Wire
Earnings Scheduled For March 15, 2022
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.